207 related articles for article (PubMed ID: 32221754)
1. Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.
Johne A; Scheible H; Becker A; van Lier JJ; Wolna P; Meyring M
Invest New Drugs; 2020 Oct; 38(5):1507-1519. PubMed ID: 32221754
[TBL] [Abstract][Full Text] [Related]
2. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.
Shitara K; Yamazaki K; Tsushima T; Naito T; Matsubara N; Watanabe M; Sarholz B; Johne A; Doi T
Jpn J Clin Oncol; 2020 Aug; 50(8):859-866. PubMed ID: 32328660
[TBL] [Abstract][Full Text] [Related]
5. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
6. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
[TBL] [Abstract][Full Text] [Related]
7. Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.
von Richter O; Massimini G; Scheible H; Udvaros I; Johne A
Br J Clin Pharmacol; 2016 Dec; 82(6):1498-1508. PubMed ID: 27483391
[TBL] [Abstract][Full Text] [Related]
8. Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.
Scheible H; Dyroff M; Seithel-Keuth A; Harrison-Moench E; Mammasse N; Port A; Bachmann A; Dong J; van Lier JJ; Tracewell W; Mitchell D
Clin Transl Sci; 2021 Nov; 14(6):2420-2430. PubMed ID: 34374206
[TBL] [Abstract][Full Text] [Related]
9. Absorption, Metabolism and Excretion of Surufatinib in Rats and Humans.
Li K; Ma S; Miao L; Fan S; Pan B; Zhang W; Su W; Xiong Y; Gu Z; Guo L; Sai Y
Curr Drug Metab; 2020; 21(5):357-367. PubMed ID: 32407271
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and disposition of imatinib mesylate in healthy volunteers.
Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.
Xiong W; Papasouliotis O; Jonsson EN; Strotmann R; Girard P
Cancer Chemother Pharmacol; 2022 May; 89(5):655-669. PubMed ID: 35385993
[TBL] [Abstract][Full Text] [Related]
12. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
13. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
14. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Meneses-Lorente G; Bentley D; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Brink A; Djebli N; Mercier F; Buchheit V; Phipps A
Invest New Drugs; 2021 Jun; 39(3):803-811. PubMed ID: 33462752
[TBL] [Abstract][Full Text] [Related]
16. Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
Xiong W; Friese-Hamim M; Johne A; Stroh C; Klevesath M; Falchook GS; Hong DS; Girard P; El Bawab S
CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):428-440. PubMed ID: 33818908
[TBL] [Abstract][Full Text] [Related]
17. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
18. Tepotinib in Non-Small-Cell Lung Cancer with
Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
[TBL] [Abstract][Full Text] [Related]
19. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Sakai H; Morise M; Kato T; Matsumoto S; Sakamoto T; Kumagai T; Tokito T; Atagi S; Kozuki T; Tanaka H; Chikamori K; Shinagawa N; Takeoka H; Bruns R; Straub J; Schumacher KM; Paik PK
Jpn J Clin Oncol; 2021 Aug; 51(8):1261-1268. PubMed ID: 34037224
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
Dowty ME; Lin J; Ryder TF; Wang W; Walker GS; Vaz A; Chan GL; Krishnaswami S; Prakash C
Drug Metab Dispos; 2014 Apr; 42(4):759-73. PubMed ID: 24464803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]